Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Inflammatory Bowel Diseases

  Free Subscription

Articles published in Gastroenterol Hepatol

Retrieve available abstracts of 108 articles:
HTML format

Single Articles

    December 2023
  1. GARCIA-ALANIS M, Toapanta-Yanchapaxi L, Reyes-Velasquez A, Mancilla F, et al
    The interrelation between anxiety and quality of life among patients with ulcerative colitis in remission.
    Gastroenterol Hepatol. 2023;46:747-753.
    PubMed     Abstract available

    November 2023
  2. DEZA DC, Julian Gomara AB, Biota EC, Beltran B, et al
    Gastroenterol Hepatol. 2023 Nov 23:S0210-5705(23)00474.
    PubMed     Abstract available

  3. PENA MEJIA LA, Ruiz Nino GV, Arteta Cueto AA
    Relation between histopathological findings, clinical severity, and the need of surgery in patients with Crohn's disease.
    Gastroenterol Hepatol. 2023 Nov 23:S0210-5705(23)00473.
    PubMed     Abstract available

  4. MANUEL BENITEZ J, Suarez-Ferrer C, Calafat M, Baston-Rey I, et al
    Paediatric to adult transition programme in inflammatory bowel disease, why do we need it?
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00469.

  5. GONZALEZ-MUNOZA C, Gely C, Gordillo J, Bertoletti F, et al
    Duration of smoking cessation in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023 Nov 15:S0210-5705(23)00470.
    PubMed     Abstract available

    October 2023
  6. SILVA ACV, Tumelero TJ, Yamamoto DR, Truppel SK, et al
    Biological therapy, surgery, and hospitalization rates for inflammatory bowel disease: an observational Latin American comparative study between adults and pediatric patients.
    Gastroenterol Hepatol. 2023 Oct 25:S0210-5705(23)00452.
    PubMed     Abstract available

  7. IZQUIERDO VP, Frias-Ordonez JS, Cuadros C, Vargas M, et al
    Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience.
    Gastroenterol Hepatol. 2023 Oct 9:S0210-5705(23)00442.
    PubMed     Abstract available

  8. PINERO G, Manosa M, Calafat M, Vayreda E, et al
    Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00439.
    PubMed     Abstract available

  9. IZQUIERDO VP, Frias-Ordonez JS, Banos FJ, Cuadros C, et al
    Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: a case series study.
    Gastroenterol Hepatol. 2023 Oct 6:S0210-5705(23)00443.
    PubMed     Abstract available

  10. LAO DOMINGUEZ FA, Fobelo Lozano MJ, Gutierrez Pizarraya A, Castro Fernandez M, et al
    Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease.
    Gastroenterol Hepatol. 2023;46:631-632.

  11. FORTUNY M, Gutierrez-Rios L, Vayreda E, Manosa M, et al
    Tofacitinib for the treatment of inflammatory condition of the ileoanal pouch refractory to infliximab.
    Gastroenterol Hepatol. 2023;46:629-630.

    August 2023
  12. SERRANO DIAZ L, Iniesta Navalon C, Gomez Espin R, Nicolas De Prado I, et al
    Comparative effectiveness and drug survival of biosimilar infliximab CPT-13 vs. reference infliximab in inflammatory bowel disease: A retrospective cohort study.
    Gastroenterol Hepatol. 2023 Aug 18:S0210-5705(23)00392.
    PubMed     Abstract available

  13. RIOS LG, Vayreda E, Calafat M, Canete F, et al
    Changes in the intensified regimen of infliximab in patients with inflammatory bowel disease in sustained remission. Reflections on a series of cases.
    Gastroenterol Hepatol. 2023 Aug 8:S0210-5705(23)00374.

  14. ARENAS A, Moreta MJ, Ordas I, Fernandez-Clotet A, et al
    De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.
    Gastroenterol Hepatol. 2023 Aug 8:S0210-5705(23)00376.
    PubMed     Abstract available

  15. DIAZ LS, Navalon CI, Espin RG, Prado IN, et al
    Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023;46:504-511.
    PubMed     Abstract available

    June 2023
  16. SUAREZ FERRER C, Martin-Arranz MD, Martin-Arranz E, Rodriguez Morata F, et al
    Current management of bowel failure due to Crohn's disease in Spain: Results of a GETECCU survey.
    Gastroenterol Hepatol. 2023;46:439-445.
    PubMed     Abstract available

  17. NAVARRO-CORREAL E, Ibarz Casas A, Agustino Rodriguez S, Marin L, et al
    Knowledge, attitudes and behaviours on smoking cessation in nurses caring for patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2023;46:468-471.

    May 2023
  18. BENITO BM, Gisbert JP, Garcia Fraile Fraile LJ, Blandino AB, et al
    Gastroenterol Hepatol. 2023 May 5:S0210-5705(23)00333.

  19. GONZALEZ-MARTINEZ A, Garcia IM, Quintas S, Chaparro M, et al
    Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics.
    Gastroenterol Hepatol. 2023 May 4:S0210-5705(23)00331.
    PubMed     Abstract available

  20. MENG XF, Lin QY, Yin HL, Li ZQ, et al
    Magnetic resonance imaging for evaluation of bowel inflammation and disease activity in Crohn's disease: A systematic review and meta-analysis.
    Gastroenterol Hepatol. 2023;46:336-349.
    PubMed     Abstract available

    April 2023
  21. PITARCH LG, Almela P, Nos P
    Leishmania infection in patients with Inflammatory Bowel Disease: case series and literature review.
    Gastroenterol Hepatol. 2023 Apr 13:S0210-5705(23)00074.
    PubMed     Abstract available

  22. MORENO EN, Lopez Gonzalez J, Saez ML
    Gastroenterol Hepatol. 2023 Apr 4:S0210-5705(23)00073.

  23. GARGALLO-PUYUELO CJ, Garcia-Mateo S, Martinez-Dominguez SJ, Gomollon F, et al
    Is the gender or age of the physician key to a good physician-patient with inflammatory bowel disease relationship?
    Gastroenterol Hepatol. 2023;46:261-265.
    PubMed     Abstract available

  24. RAMOS L, Carrillo-Palau M, Alonso-Abreu I, Reygosa C, et al
    COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
    Gastroenterol Hepatol. 2023;46:255-260.
    PubMed     Abstract available

    March 2023
  25. CASTILLO-REGALADO E, Rios R, Arajol C, Gely C, et al
    Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
    Gastroenterol Hepatol. 2023;46:164-170.
    PubMed     Abstract available

    February 2023
  26. CUFFI MS, Arias FA, Piudo AE, Vicens DG, et al
    Optimizing treatment of mild to moderate ulcerative colitis: CU-Forum Delphi Consensus.
    Gastroenterol Hepatol. 2023 Feb 15:S0210-5705(23)00034.
    PubMed     Abstract available

    January 2023
  27. FUXMAN C, Sicilia B, Linares ME, Lopez SG, et al
    GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline.
    Gastroenterol Hepatol. 2023 Jan 30:S0210-5705(23)00014.
    PubMed     Abstract available

  28. CASTANO LLANO R, Molina Meneses SP, Puerta JD, Escobar RM, et al
    Ileal reservoir-associated complications in ulcerative colitis versus familial adenomatous polyposis: Impact on patient quality of life.
    Gastroenterol Hepatol. 2023;46:39-47.
    PubMed     Abstract available

    December 2022
  29. FERREIRO-IGLESIAS R, Piqueras M, Ricart E, Sempere L, et al
    Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis on the importance, screening and vaccination in inflammatory bowel disease patients.
    Gastroenterol Hepatol. 2022;45:805-818.
    PubMed     Abstract available

  30. RUIZ-CERULLA A, Rodriguez-Alonso L, Rodriguez-Moranta F, Guardiola J, et al
    A high adalimumab induction dosing regimen achieves clinical and endoscopic remission in super-refractory ulcerative colitis.
    Gastroenterol Hepatol. 2022;45:780-781.

  31. PARRA-IZQUIERDO V, Sarmiento CF, Frias-Ordonez JS, Vargas M, et al
    Clinical and therapeutic characterisation of a multicentre cohort of patients with inflammatory bowel disease in Colombia.
    Gastroenterol Hepatol. 2022 Dec 1:S0210-5705(22)00278.
    PubMed     Abstract available

    November 2022
  32. VICENS DG, Belinchon MR, Mateu PN, Elena Pejenaute Labari M, et al
    Spanish Society of Primary Care Physicians (SEMERGEN) and Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) survey on the management of patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022 Nov 16:S0210-5705(22)00269.
    PubMed     Abstract available

  33. QUERA R, Nunez P, Sicilia B, Flores L, et al
    Corticosteroids in Inflammatory Bowel Disease: Are they still a therapeutic option?
    Gastroenterol Hepatol. 2022 Nov 11. pii: S0210-5705(22)00263.
    PubMed     Abstract available

  34. DAVIS GONZALEZ MR, Ballester MP, Romero-Gonzalez E, Sanchez-Pardo AM, et al
    Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors.
    Gastroenterol Hepatol. 2022 Nov 11:S0210-5705(22)00267.
    PubMed     Abstract available

  35. PARRA-IZQUIERDO V, Frias-Ordonez JS, Marquez JR, Juliao-Banos F, et al
    Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
    Gastroenterol Hepatol. 2022 Nov 10. pii: S0210-5705(22)00266.
    PubMed     Abstract available

  36. JULIAO-BANOS F, Osorio L, Carvajal J, Mosquera-Klinger G, et al
    Clinical characteristics and treatment of perianal fistulising Crohn's disease in Colombia: Results of a multicentric registry.
    Gastroenterol Hepatol. 2022;45:690-696.
    PubMed     Abstract available

  37. HERNANDEZ CAMBA A, Ramos L, Madrid Alvarez MB, Perez-Mendez L, et al
    Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.
    Gastroenterol Hepatol. 2022;45:668-676.
    PubMed     Abstract available

  38. DEL HOYO J, Millan M, Garrido-Marin A, Nos P, et al
    Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?
    Gastroenterol Hepatol. 2022;45:697-705.
    PubMed     Abstract available

  39. LADRON ABIA P, Minguez Sabater A, Saez Gonzalez E, Beltran Niclos B, et al
    Rescue therapy with oral cyclosporine after use of ustekinumab in ulcerative colitis resistant to multiple treatments.
    Gastroenterol Hepatol. 2022;45:735-736.

    October 2022
  40. CONSTANZA BAY M, Paulina Nunez F, Quera R, Yarur AJ, et al
    Current perspectives on pediatric inflammatory bowel disease focusing on Transitional care management. What should we consider?"
    Gastroenterol Hepatol. 2022 Oct 12. pii: S0210-5705(22)00229.
    PubMed     Abstract available

  41. GELY C, Gordillo J, Bertoletti F, Gonzalez-Munoza C, et al
    Perception of the need for dietary advice and dietary modifications in inflammatory bowel disease patients.
    Gastroenterol Hepatol. 2022 Oct 12. pii: S0210-5705(22)00231.
    PubMed     Abstract available

  42. LADRON ABIA P, Alonso N, Minguez Sabater A, Gimeno Torres M, et al
    The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease.
    Gastroenterol Hepatol. 2022;45:614-620.
    PubMed     Abstract available

  43. WAH-SUAREZ MI, Vazquez MAM, Bosques-Padilla FJ
    Inflammatory bowel disease: The role of commensal microbiome in immune regulation.
    Gastroenterol Hepatol. 2022;45:626-636.
    PubMed     Abstract available

    September 2022
  44. NUNEZ L, Mesonero F, Rodriguez de Santiago E, Die J, et al
    High incidence of surgery and initiation of medical therapies after colectomy for ulcerative colitis or inflammatory bowel disease unclassified.
    Gastroenterol Hepatol. 2022 Sep 14. pii: S0210-5705(22)00216.
    PubMed     Abstract available

  45. LATRAS-CORTES I, Alvarez PS, Prada MG, Sanz NC, et al
    Efficacy, persistence and optimization of ustekinumab in ulcerative colitis: clinical practice data.
    Gastroenterol Hepatol. 2022 Sep 13. pii: S0210-5705(22)00211.

    August 2022
  46. ALGABA A, Guerra I, Castro S, Bermejo F, et al
    SARS-CoV-2 infection in patients with inflammatory bowel disease in the second-third wave and its comparison with data of first wave of pandemic.
    Gastroenterol Hepatol. 2022;45:572-573.

  47. ROMERO RK, Magro DO, Queiroz NSF, Damiao AOMC, et al
    Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
    Gastroenterol Hepatol. 2022;45:499-506.
    PubMed     Abstract available

    May 2022
  48. ROIG CA, Ferrer CS, Garcia JLR, Cordon JP, et al
    "Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease".
    Gastroenterol Hepatol. 2022 May 20. pii: S0210-5705(22)00156.
    PubMed     Abstract available

  49. ALGABA A, Romero S, Granja A, Garza D, et al
    Serological Response To Vaccines Against Sars-Cov-2 In Patients With Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2022 May 20. pii: S0210-5705(22)00154.
    PubMed     Abstract available

  50. LATRAS CORTES I, Sierra-Ausin M
    Tacrolimus plus ustekinumab in refractory ulcerative colitis.
    Gastroenterol Hepatol. 2022 May 13. pii: S0210-5705(22)00145.

  51. MARIA SR, Jesus B, Luis FS, Lara A, et al
    Incidence, and natural history of inflammatory bowel disease in Castilla y Leon: prospective and multicenter epidemiological study.
    Gastroenterol Hepatol. 2022 May 12. pii: S0210-5705(22)00139.
    PubMed     Abstract available

  52. SURIA C, Bosca-Watts MM, Navarro P, Tosca J, et al
    Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.
    Gastroenterol Hepatol. 2022;45:383-389.
    PubMed     Abstract available

  53. RAMOS L, Ramos-Rodriguez J, Barreda R, Gutierrez-Nicolas F, et al
    Adherence to subcutaneous biologic treatment for inflammatory bowel disease.
    Gastroenterol Hepatol. 2022;45:335-341.
    PubMed     Abstract available

    April 2022
  54. MERINO GALLEGO E, Gallardo Sanchez F
    Prevalence of extra-intestinal manifestations, risk factors and therapeutic risk factors and therapeutic management in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022;45 Suppl 1:4-5.

  55. MARQUES-CAMI M, Garcia-Guinon A, Garreta J, Volta T, et al
    A 61-year-old patient with Crohn's disease and severe postoperative recurrence responding to JAK inhibitor ruxolitinib for polycythemia vera treatment.
    Gastroenterol Hepatol. 2022;45 Suppl 1:16-17.

  56. ESTEBANEZ FERRERO B, Ruiz Pardo J, Velasco Albendea FJ, Vidana Marquez E, et al
    Tuberculosis mimicking Crohn's disease and respiratory infection by COVID-19.
    Gastroenterol Hepatol. 2022;45 Suppl 1:13-15.

    March 2022
  57. NUNEZ F P, Quera R, Bay C, Thomson P, et al
    Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases.
    Gastroenterol Hepatol. 2022;45:223-230.
    PubMed     Abstract available

  58. MINGUEZ SABATER A, Conde Amiel I, Ladron Abia P, Martinez Delgado S, et al
    Characteristics and impact of sex in a cohort of patients with primary sclerosing cholangitis: Experience of a transplant center in the Mediterranean basin.
    Gastroenterol Hepatol. 2022;45:177-185.
    PubMed     Abstract available

  59. MARIN-JIMENEZ I, Acosta MB, Esteve M, Castro-Laria L, et al
    Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study.
    Gastroenterol Hepatol. 2022;45:165-176.
    PubMed     Abstract available

    February 2022
  60. REFAIE E, Garcia Mateo S, Martinez Dominguez SJ, Gargallo-Puyuelo CJ, et al
    Impact of the lockdown period due to the COVID-19 pandemic in patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2022;45:114-122.
    PubMed     Abstract available

  61. ROCHA HC, Vilela EG
    Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
    Gastroenterol Hepatol. 2022;45:83-90.
    PubMed     Abstract available

    January 2022
  62. MEARIN F, Sans M, Balboa A
    Relevance and needs of Irritable Bowel Syndrome (IBS): comparison with Inflammatory Bowel Disease (IBD).
    Gastroenterol Hepatol. 2022 Jan 17. pii: S0210-5705(21)00332.
    PubMed     Abstract available

  63. YEBRA CARMONA J, Poza Cordon J, Suarez Ferrer C, Martin Arranz E, et al
    Correlation between endoscopy and intestinal ultrasound for the evaluation of postoperative recurrence of Crohn's disease.
    Gastroenterol Hepatol. 2022;45:40-46.
    PubMed     Abstract available

  64. ROJAS-FERIA M, Rodriguez-Fernandez M, Castro-Fernandez M, Suarez-Garcia E, et al
    Vedolizumab-induced cholestatic liver injury.
    Gastroenterol Hepatol. 2022;45:64-65.

    December 2021
  65. ZAVALA-SOLARES MR, Salazar-Salas L, Yamamoto-Furusho JK
    Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease.
    Gastroenterol Hepatol. 2021;44:711-718.
    PubMed     Abstract available

    November 2021
  66. ZHANG X, Ma L, Zhang C, Hou B, et al
    Silencing LncRNA-DANCR attenuates inflammation and DSS-induced endothelial injury through miR-125b-5p.
    Gastroenterol Hepatol. 2021;44:644-653.
    PubMed     Abstract available

    October 2021
  67. CALVET X, Carpio D, Rodriguez-Lago I, Garcia-Vicuna R, et al
    Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
    Gastroenterol Hepatol. 2021;44:587-598.
    PubMed     Abstract available

    August 2021
  68. FERREIRO-IGLESIAS R, Hernandez-Camba A, Serrano Labajos R, Rodriguez-Lago I, et al
    SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project.
    Gastroenterol Hepatol. 2021 Aug 25. pii: S0210-5705(21)00246.
    PubMed     Abstract available

  69. LIDON RV, Lopez SG, Roche PC, Miguel Boudet Barraca J, et al
    Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient s perspective: IBD-control, EII-control.
    Gastroenterol Hepatol. 2021 Aug 21. pii: S0210-5705(21)00243.
    PubMed     Abstract available

  70. RODRIGUEZ-LAGO I, Mesonero F, Hijos-Mallada G, Canas M, et al
    Gastroenterol Hepatol. 2021 Aug 13. pii: S0210-5705(21)00227.
    PubMed     Abstract available

  71. GENE M, Alguersuari A, Pons F, Minambres C, et al
    Serrated epithelial lesion with dysplasia as a precursor to small bowel carcinoma associated with Crohn's disease.
    Gastroenterol Hepatol. 2021;44:489-490.

    July 2021
  72. LORAS C, Manosa M, Andujar X, Sanchiz V, et al
    Recommendations of the spanish group on crohn's disease and ulcerative colitis (geteccu) on the treatment of strictures in crohn's disease.
    Gastroenterol Hepatol. 2021 Jul 15. pii: S0210-5705(21)00219.
    PubMed     Abstract available

    June 2021
  73. HIJOS-MALLADA G, Sostres C, Gomollon F
    NSAIDs, gastrointestinal toxicity and Inflammatory Bowel Disease.
    Gastroenterol Hepatol. 2021 Jun 19. pii: S0210-5705(21)00201.
    PubMed     Abstract available

  74. FORTUNY BAUZA M, Canete Pizarro F, Calm Salvans A, Calafat Sard M, et al
    Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab.
    Gastroenterol Hepatol. 2021 Jun 9. pii: S0210-5705(21)00188.

  75. GONZALEZ-MUNOZA C, Briones J, Sang Park H, Garcia-Planella E, et al
    Marginal zone lymphoma under anti-TNF treatment in Crohn disease.
    Gastroenterol Hepatol. 2021 Jun 9. pii: S0210-5705(21)00193.

  76. JULIAO-BANOS F, Arrubla M, Osorio L, Camargo J, et al
    Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
    Gastroenterol Hepatol. 2021;44:398-404.
    PubMed     Abstract available

    May 2021
  77. PEREZ DE ARCE E, Quera R, Beltran CJ, Madrid AM, et al
    Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis?
    Gastroenterol Hepatol. 2021 May 20. pii: S0210-5705(21)00143.
    PubMed     Abstract available

  78. SEMPERE L, Bernabeu P, Cameo J, Gutierrez A, et al
    Evolution of the emotional impact in patients with early Inflammatory Bowel Disease during and after Covid-19 lockdown.
    Gastroenterol Hepatol. 2021 May 20. pii: S0210-5705(21)00145.

    April 2021
  79. GONZALEZ AE, Castillejo ON, Sainz IF, Lopez-Garcia A, et al
    Use of capsule endoscopy in Inflammatory Bowel Disease in clinical practice in Spain. Results from a national survey.
    Gastroenterol Hepatol. 2021 Apr 16. pii: S0210-5705(21)00110.
    PubMed     Abstract available

  80. NUNEZ F P, Quera R, Sepulveda E, Simian D, et al
    Pregnancy in Inflammatory Bowel Disease: Experience of a Chilean cohort.
    Gastroenterol Hepatol. 2021;44:277-285.
    PubMed     Abstract available

  81. DIAZ ALCAZAR MDM, Martin-Lagos Maldonado A, Garcia-Consuegra Ruiz-Aragon FM, Herrera Mercader MDC, et al
    Liver abscesses as an initial manifestation of Crohn's disease.
    Gastroenterol Hepatol. 2021;44:310-311.

  82. DE LOS MOZOS RUANO A, Casas Deza D, Calvo Galindo R, Solana Hidalgo MP, et al
    Methotrexate pneumonitis in a patient with Crohn's disease, during the COVID pandemic: An unusual clinical case and review of the literature.
    Gastroenterol Hepatol. 2021;44:302-303.

  83. HALLOUCH TOUTOUH S, Lazaro Saez M, Hernandez Martinez A
    Ustekinumab for prevention of postoperative recurrence: Our clinical experience.
    Gastroenterol Hepatol. 2021;44:296-297.

    February 2021
  84. SICILIA B, Vicente R, Arias L, Echarri A, et al
    Recommendations of the Spanish Working Group on Crohn's disease and ulcerative colitis (Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients.
    Gastroenterol Hepatol. 2021 Feb 13. pii: S0210-5705(21)00043.
    PubMed     Abstract available

  85. CRISTINA SF, Angeles RRM, Maria SA, Luis RGJ, et al
    Nutricional Habits In Patients With Inflammatory Bowel Disease: Perception Of Patients And Health Professionals.
    Gastroenterol Hepatol. 2021 Feb 2. pii: S0210-5705(21)00014.

  86. RODRIGUEZ C, Elosua A, Prieto C, Perez E, et al
    COLECTOMY RATE IN ULCERATIVE COLITIS 15 YEARS AFTER DIAGNOSIS: Results from the 2001-2003 Navarra cohort.
    Gastroenterol Hepatol. 2021 Feb 2. pii: S0210-5705(21)00003.
    PubMed     Abstract available

  87. PENNA FGC, Rosa RM, Pereira FH, Cunha PFS, et al
    Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease.
    Gastroenterol Hepatol. 2021;44:87-95.
    PubMed     Abstract available

    January 2021
  88. NAVARRO-CORREAL E, Borruel N, Robles V, de Guise CH, et al
    Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease.
    Gastroenterol Hepatol. 2021 Jan 27. pii: S0210-5705(21)00005.
    PubMed     Abstract available

  89. BLASCO PATINO F, Nicolae MV, Navarro E
    Acute submandibular sialadenitis in a patient with Crohn's disease being treated with infliximab.
    Gastroenterol Hepatol. 2021;44:49-50.

    December 2020
  90. MUNOZ F, Ripolles T, Poza Cordon J, de Las Heras Paez de la Cadena B, et al
    Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of abdominal ultrasound in inflammatory bowel disease.
    Gastroenterol Hepatol. 2020 Dec 11. pii: S0210-5705(20)30214.
    PubMed     Abstract available

    November 2020
  91. RUBIANO MR, Medina GR, Perez-Riveros ED, Panqueva RDPL, et al
    Proctitis is not always ulcerative colitis.
    Gastroenterol Hepatol. 2020 Nov 25. pii: S0210-5705(20)30441.

  92. QUERA R, Simian D, Flores L, Ibanez P, et al
    Gastroenterol Hepatol. 2020 Nov 21. pii: S0210-5705(20)30438.

  93. QUERA R, Pizarro G, Simian D, Ibanez P, et al
    Impact of COVID-19 on a cohort of patients with inflammatory bowel disease at a specialised centre in Chile.
    Gastroenterol Hepatol. 2020 Nov 20. pii: S0210-5705(20)30431.

  94. LADRON ABIA P, Alcala Vicente C, Martinez Delgado S, Bastida Paz G, et al
    Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
    Gastroenterol Hepatol. 2020 Nov 13. pii: S0210-5705(20)30364.

  95. MINGUEZ SABATER A, Martinez Delgado S, Ladron Abia P, Bastida G, et al
    Skin injuries associated with biological therapy in inflammatory bowel disease: beyond psoriasis.
    Gastroenterol Hepatol. 2020 Nov 11. pii: S0210-5705(20)30378.

  96. LUCAS RAMOS J, Suarez Ferrer C, Poza Cordon J, Sanchez Azofra M, et al
    Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease.
    Gastroenterol Hepatol. 2020 Nov 7. pii: S0210-5705(20)30387.
    PubMed     Abstract available

  97. PEREZ DE ARCE E, Quera R, Nunez P, Simian D, et al
    Management of acute severe ulcerative colitis in chile: Experience of a multidisciplinary team.
    Gastroenterol Hepatol. 2020 Nov 6. pii: S0210-5705(20)30400.

    October 2020
  98. QUERA R, Simian D, Nunez P, Flores L, et al
    Are patients with inflammatory bowel disease receiving adequate immunisation?
    Gastroenterol Hepatol. 2020 Oct 29. pii: S0210-5705(20)30303.
    PubMed     Abstract available

  99. EZQUERRA A, Resina E, Montes A, Alvarez-Male T, et al
    Pericardial effusion associated with mesalamine treatment in a patient with ulcerative colitis.
    Gastroenterol Hepatol. 2020 Oct 20. pii: S0210-5705(20)30377.

  100. NUNEZ P, Garcia Mateo S, Quera R, Gomollon F, et al
    Inflammatory bowel disease and the risk of cardiovascular diseases.
    Gastroenterol Hepatol. 2020 Oct 20. pii: S0210-5705(20)30375.
    PubMed     Abstract available

  101. NUNEZ F P, Quera R, Simian D, Flores L, et al
    Infliximab in inflammatory bowel disease. Is premedication necessary?
    Gastroenterol Hepatol. 2020 Oct 20. pii: S0210-5705(20)30362.
    PubMed     Abstract available

  102. NUNEZ F P, Mahadevan U, Quera R, Bay C, et al
    Treat-to-target approach in the management of inflammatory Bowel disease.
    Gastroenterol Hepatol. 2020 Oct 15. pii: S0210-5705(20)30318.
    PubMed     Abstract available

  103. LOPEZ GONZALEZ J, Hernandez Martinez A, Lazaro Saez M, Vega Saenz JL, et al
    Experience with tofacitinib in patients with refractary ulcerative colitis.
    Gastroenterol Hepatol. 2020 Oct 10. pii: S0210-5705(20)30309.

  104. GARCIA-ALANIS M, Quiroz-Casian L, Castaneda-Gonzalez H, Arguelles-Castro P, et al
    Prevalence of mental disorder and impact on quality of life in inflammatory bowel disease.
    Gastroenterol Hepatol. 2020 Oct 8. pii: S0210-5705(20)30304.
    PubMed     Abstract available

  105. DEL HOYO J, Aguas M
    Implementing telemedicine in inflammatory bowel disease: Is COVID-19 the definitive trigger?
    Gastroenterol Hepatol. 2020;43:415-417.

    April 2020
  106. POUS S, Frasson M, Jimenez R, Pamies J, et al
    Relevance of dynamic studies with magnetic resonance enterography in Crohn's disease.
    Gastroenterol Hepatol. 2020;43:179-187.
    PubMed     Abstract available

    March 2020
  107. CASAS DEZA D, Garcia Lopez S, Lafuente Blasco M, Vicente Lidon R, et al
    Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort.
    Gastroenterol Hepatol. 2020;43:126-132.
    PubMed     Abstract available

    January 2020
  108. GELY C, Marin L, Gordillo J, Manosa M, et al
    Impact of pain associated with the subcutaneous administration of adalimumab.
    Gastroenterol Hepatol. 2020;43:9-13.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.